Molecular detection and clinicopathological characteristics of advanced/recurrent biliary tract carcinomas harboring the FGFR2 rearrangements: a prospective observational study (PRELUDE Study)

Authors:

Abstract
Background: Fibroblast growth factor receptor 2(FGFR2) rearrangement is expected to be a novel therapeutic target in advanced/recurrent biliary tract cancer (BTC). However, efficient detection and the exact frequency ofFGFR2rearrangements among patients with advanced/recurrent BTC have not been determined, and the clinical characteristics ofFGFR2rearrangement-positive patients have not been fully elucidated. We aimed to determine the frequency ofFGFR2rearrangement-positive patients among those with advanced/recurrent BTC and elucidate their clinicopathological characteristics.Methods: Paraffin-embedded tumor samples from formalin-fixed surgical or biopsy specimens of patients with advanced/recurrent BTC were analyzed for positivity ofFGFR2rearrangement by fluorescent in situ hybridization (FISH). RNA sequencing was performed on samples from all FISH-positive and part of FISH-negative patients.Results: A total of 445 patients were enrolled. FISH was performed on 423 patients (272 patients with intrahepatic cholangiocarcinoma (ICC), 83 patients with perihilar cholangiocarcinoma (PCC), and 68 patients with other BTC). Twenty-one patients with ICC and four patients with PCC were diagnosed asFGFR2-FISH positive. Twenty-three of the 25 FISH-positive patients (20 ICC and 3 PCC) were recognized asFGFR2rearrangement positive by targeted RNA sequencing. Younger age (≤ 65 years;p = 0.018) and HCV Ab- and/or HBs Ag-positivity (p = 0.037) were significantly associated with the presence ofFGFR2rearrangement (logistic regression).Conclusions: FGFR2rearrangement was identified in ICC and PCC patients, and was associated with younger age and history of hepatitis viral infection.
Funding Information
  • Ministry of Health, Labour and Welfare (Research on the establishment of treatment for biliary tract cancer, Clinical Trial on Development of New Drugs and Medical Devices)
  • Ministry of Education, Culture, Sports, Science and Technology (18K07956)
  • the National Cancer Center Research and Development Fund (23-A-15)

This publication has 28 references indexed in Scilit: